1. ErbB Receptors as Prognostic and Therapeutic Drug Targets in Bone and Soft Tissue Sarcomas
   Hongsheng Wang et al, 2014, Cancer Investigation CrossRef
2. Advances in studies of tyrosine kinase inhibitors and their acquired resistance
   Qinlian Jiao et al, 2018, Molecular Cancer CrossRef
3. Metabolic reprogramming in osteosarcoma
   Yulu Shi et al, 2023, Pediatric Discovery CrossRef
4. Anoikis resistant mediated by FASN promoted growth and metastasis of osteosarcoma
   Tianhao Sun et al, 2019, Cell Death & Disease CrossRef
5. Precision medicine for diagnosis and treatment of osteosarcoma
   Rui Wang et al, 2016, Oncology and Translational Medicine CrossRef
6. Exploiting Kinase Inhibitors for Cancer Treatment: An Overview of Clinical Results and Outlook
   Athina Moschopoulou et al, 2020, Proteinkinase Inhibitors CrossRef
7. Alantolactone suppresses human osteosarcoma through the PI3K/AKT signaling pathway
   Yong Zhang et al, 2019, Molecular Medicine Reports CrossRef
8. Targeting epidermal growth factor receptor pathway with irreversible tyrosine kinase inhibitor
   Fatma Sagir et al, 2019, Turkish Journal of Biochemistry CrossRef
9. Signal Pathways and microRNAs in Osteosarcoma Growth and the Dual Role of Mesenchymal Stem Cells in Oncogenesis
   Natalia Todosenko et al, 2023, International Journal of Molecular Sciences CrossRef
10. Crosstalk between osteoprotegerin (OPG), fatty acid synthase (FASN) and, cycloxygenase-2 (COX-2) in breast cancer: implications in carcinogenesis
    Sudeshna Goswami et al, 2016, Oncotarget CrossRef
11. PI3K/Akt signaling in osteosarcoma
    Jian Zhang et al, 2015, Clinica Chimica Acta CrossRef
12. Using activation status of signaling pathways as mechanism-based biomarkers to predict drug sensitivity
    Alicia Amadoz et al, 2015, Scientific Reports CrossRef
13. Trastuzumab-modified DM1-loaded nanoparticles for HER2+breast cancer treatment: anin vitroandin vivostudy
    Ling Rong et al, 2017, Artificial Cells, Nanomedicine, and Biotechnology CrossRef
14. Tizanidine hydrochloride exhibits a cytotoxic effect on osteosarcoma cells through the PI3K/AKT signaling pathway
    Xue-Wu Xing et al, 2019, Journal of International Medical Research CrossRef
15. Prognostic and Therapeutic Utility of Variably Expressed Cell Surface Receptors in Osteosarcoma
    Yoav Zvi et al, 2021, Sarcoma CrossRef
16. Tumour fatty acid metabolism in the context of therapy resistance and obesity
    Andrew J. Hoy et al, 2021, Nature Reviews Cancer CrossRef
17. Prognostic significance of the expression of HER family members in primary osteosarcoma
    Sheng‑Lin Wang et al, 2018, Oncology Letters CrossRef
18. The Future of HER2-Targeted Treatment for Osteosarcoma: Lessons from the Negative Trastuzumab Deruxtecan Results
    Kenji Nakano, 2023, International Journal of Molecular Sciences CrossRef
19. Increased expression of fatty acid synthase and acetyl-CoA carboxylase in the prefrontal cortex and cerebellum in the valproic acid model of autism
    Jianling Chen et al, 2016, Experimental and Therapeutic Medicine CrossRef